Moderna
Search results
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
We’re making a difference in the health of people around the world by producing next generation vaccines that are accessible to more people. We stand strong against infectious diseases and viral ...
Our vaccine technology combines power and speed with the immunogenicity-enhancing properties of our Matrix-M™ adjuvant to efficiently produce highly immunogenic particles targeting some of the most pressing viral infectious diseases. Learn about our unique technology.
Novavax is funded by a mix of private and public investment. In 2015, Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization.
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).
Sep 28, 2022 · The Novavax vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vaccination for 3 months following the infection. Should pregnant and breastfeeding women be vaccinated?
Novavax is here to make a difference. We’re a biotech company focused on developing life-saving vaccines to fight infectious diseases. We use solid science tested by decades of research to develop vaccines.
Oct 16, 2023 · Novavax’s protein-based vaccine is the latest FDA-authorized COVID booster available this fall. Here’s what you should know
The FDA amended the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. The updated vaccine...
Oct 17, 2023 · The Novavax COVID-19 Vaccine, Adjuvanted, a monovalent vaccine, has been updated to include the spike protein from the SARS-CoV-2 Omicron variant lineage XBB.1.5 (2023-2024 formula).
